Clinical Trials · NCT07523711

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

Name: Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 1Maridebart cafraglutide

Phase: Phase 1
Recruitment status: Active Not Recruiting
Sponsor: Amgen
Enrollment: 49
Start date: Apr 2026
Locations: 2 sites, United States
Primary endpoint: Maximum Observed Concentration (Cmax) of COC

View Maridebart-Cafraglutide compound reference